Business
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"Basilea Pharmaceutica International Ltd, Allschwil","displaySize":"","headline":null,"caption":"Basilea Pharmaceutica International Ltd, Allschwil","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/863aV4U6H3aPDpGW_iaFpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7","width":300,"height":102}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Allschwil, Switzerland, February 25, 2026","length":41,"tagName":"p"},{"type":"text","content":"Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 6 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.","length":689,"tagName":"p"},{"type":"text","content":"David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased to receive the continued funding from BARDA to support the further development of our novel antibiotic ceftibuten-ledaborbactam, including the preparation of clinical phase 3 studies. We believe that, by addressing the critical unmet medical need for the oral treatment of cUTIs caused by multidrug-resistant bacteria, this candidate holds a strong promise for patients suffering from these severe infections.”","length":487,"tagName":"p"},{"type":"text","content":"Under the terms of the specific Contract[1] with BARDA, upon completion of predefined milestones, Basilea could be reimbursed for a significant proportion of the further development costs required to bring the candidate to market, including the planned phase 3 clinical studies. After the current ...